Common use of Financial Provisions Clause in Contracts

Financial Provisions. The Sponsor (through CRO, if applicable) will provide funding in support of the Clinical Trial, as set out in Annex 3. All payments shall occur on the conditions as set out in this Annex 3. In the event that amendments to the Protocol require changes to the Clinical Trial financing arrangements, an amended financial schedule will be agreed upon and signed by the Parties which will replace the existing Annex 3. If the Agreement is terminated for one of the reasons in clauses 12.2, 12.3 or 12.5, except for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f), and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, the Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment to the Principal Investigator and/or the Institution up to the date of termination in accordance with Annex 3, and also all expenditure falling due for payment after the date of termination which arises from uncancellable commitments reasonably and necessarily incurred by the Principal Investigator and/or Institution for the performance of the Clinical Trial prior to the date of termination, in accordance with Annex 3. In the case of termination for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f), and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment of properly performed services up to the date of the material breach by the Institution and/or the Principal Investigator in accordance with Annex 3. In case of termination for fraud, bribery or corruption, Sponsor will not pay for fees and expenditures directly related to such fraud, bribery or corruption. In the event of early termination, if payment has been made by the Sponsor (through CRO if applicable) to the Institution or the Principal Investigator in advance for work not completed in accordance with Article 13.3, the Institution and/or the Principal Investigator shall issue a credit note and repay the remainder of the monies within 45 days of receipt of written notice from the Sponsor and/or CRO

Financial Provisions. The Sponsor (through CRO, if applicable) will provide funding in support of the Clinical Trial, as set out in Annex 3. All payments shall occur on the conditions as set out in this Annex 3. The Parties agree that no payments are being provided for the purpose of inducing anyone to purchase or prescribe any drugs, devices or products. In addition, Site shall not (i) xxxx any patient, insurer, or governmental agency for any items, visits, services or expenses provided or paid for by, or on behalf of, Sponsor, or (ii) provide any money or item of value to any government official or representative to improperly influence government actions. In the event that amendments to the Protocol require changes to the Clinical Trial financing arrangements, an amended financial schedule will be agreed upon and signed by the Parties which will replace the existing Annex 3. If the Agreement is terminated for one of the reasons in clauses 12.2, 12.3 or 12.5, except for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)12.2.f, and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, the Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment to the Principal Investigator and/or the Institution up to the date of termination in accordance with Annex 3, and also all expenditure falling due for payment after the date of termination which arises from uncancellable commitments reasonably and necessarily incurred by the Principal Investigator and/or Institution for the performance of the Clinical Trial prior to the date of termination, in accordance with Annex 3. In the case of termination for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)12.2.f, and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment of properly performed services up to the date of the material breach by the Institution and/or the Principal Investigator in accordance with Annex 3. In case of termination for fraud, bribery or corruption, Sponsor will not pay for fees and expenditures directly related to such fraud, bribery or corruption. In the event of early termination, if payment has been made by the Sponsor (through CRO if applicable) to the Institution or the Principal Investigator in advance for work not completed in accordance with Article 13.3, the Institution and/or the Principal Investigator shall issue a credit note and repay the remainder of the monies within 45 days of receipt of written notice from the Sponsor and/or CRO

Financial Provisions. The Sponsor (through CRO, if applicable) will provide funding in support of the Clinical Trial, as set out in Annex 3. All payments shall occur on the conditions as set out in this Annex 3. In the event that amendments to the Protocol require changes to the Clinical Trial financing arrangements, an amended financial schedule will be agreed upon and signed by the Parties which will replace the existing Annex 3. If the Agreement is terminated for one of the reasons in clauses 12.2, 12.3 or 12.5, except for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)12.2.f, and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, the Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment to the Principal Investigator and/or the Institution up to the date of termination in accordance with Annex 3, and also all expenditure falling due for payment after the date of termination which arises from uncancellable commitments reasonably and necessarily incurred by the Principal Investigator and/or Institution for the performance of the Clinical Trial prior to the date of termination, in accordance with Annex 3. In the case of termination for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)12.2.f, and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment of properly performed services up to the date of the material breach by the Institution and/or the Principal Investigator in accordance with Annex 3. In case of termination for fraud, bribery or corruption, Sponsor will not pay for fees and expenditures directly related to such fraud, bribery or corruption. In the event of early termination, if payment has been made by the Sponsor (through CRO if applicable) to the Institution or the Principal Investigator in advance for work not completed in accordance with Article 13.3, the Institution and/or the Principal Investigator shall issue a credit note and repay the remainder of the monies within 45 days of receipt of written notice from the Sponsor and/or CRO

Financial Provisions. The Sponsor (through CRO, if applicable) will provide funding in support of the Clinical Trial, as set out in Annex 3. All payments shall occur on the conditions as set out in this Annex 3. The Parties agree that the compensation being paid hereunder is fair market value for the services being provided, and that no payments are being provided for the purpose of inducing anyone to purchase or prescribe any drugs, devices or products. In addition, Site shall not (i) xxxx any patient, insurer, or governmental agency for any items, visits, services or expenses provided or paid for by, or on behalf of, Sponsor, or (ii) provide any money or item of value to any government official or representative to improperly influence government actions. In the event that amendments to the Protocol require changes to the Clinical Trial financing arrangements, an amended financial schedule will be agreed upon and signed by the Parties which will replace the existing Annex 3. If the Agreement is terminated for one of the reasons in clauses 12.2., 12.3 12.3. or 12.5., except for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)f., and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, the Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment to the Principal Investigator and/or the Institution up to the date of termination in accordance with Annex 3, and also all expenditure falling due for payment after the date of termination which arises from uncancellable commitments reasonably and necessarily incurred by the Principal Investigator and/or Institution for the performance of the Clinical Trial prior to the date of termination, in accordance with Annex 3. In the case of termination for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)f., and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment of properly performed services up to the date of the material breach by the Institution and/or the Principal Investigator in accordance with Annex 3. In case of termination for fraud, bribery or corruption, Sponsor will not pay for fees and expenditures directly related to such fraud, bribery or corruption. In the event of early termination, if payment has been made by the Sponsor (through CRO if applicable) to the Institution or the Principal Investigator in advance for work not completed in accordance with Article 13.3., the Institution and/or the Principal Investigator shall issue a credit note and repay the remainder of the monies within 45 days of receipt of written notice from the Sponsor and/or CRO

Financial Provisions. The Sponsor (through CRO, if applicable) will provide funding in support of the Clinical Trial, as set out in Annex 3. All payments shall occur on the conditions as set out in this Annex 3. The Parties agree that the compensation being paid hereunder is fair market value for the services being provided, and that no payments are being provided for the purpose of inducing anyone to purchase or prescribe any drugs, devices or products. In addition, Site shall not (i) bill any patient, insurer, or governmental agency for any items, visits, services or expenses provided or paid for by, or on behalf of, Sponsor, or (ii) provide any money or item of value to any government official or representative to improperly influence government actions. In the event that amendments to the Protocol require changes to the Clinical Trial financing arrangements, an amended financial schedule will be agreed upon and signed by the Parties which will replace the existing Annex 3. If the Agreement is terminated for one of the reasons in clauses 12.2., 12.3 12.3. or 12.5., except for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)f., and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, the Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment to the Principal Investigator and/or the Institution up to the date of termination in accordance with Annex 3, and also all expenditure falling due for payment after the date of termination which arises from uncancellable commitments reasonably and necessarily incurred by the Principal Investigator and/or Institution for the performance of the Clinical Trial prior to the date of termination, in accordance with Annex 3. In the case of termination for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)f., and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment of properly performed services up to the date of the material breach by the Institution and/or the Principal Investigator in accordance with Annex 3. In case of termination for fraud, bribery or corruption, Sponsor will not pay for fees and expenditures directly related to such fraud, bribery or corruption. In the event of early termination, if payment has been made by the Sponsor (through CRO if applicable) to the Institution or the Principal Investigator in advance for work not completed in accordance with Article 13.3., the Institution and/or the Principal Investigator shall issue a credit note and repay the remainder of the monies within 45 days of receipt of written notice from the Sponsor and/or CRO

Financial Provisions. The Sponsor (through CRO, if applicable) will provide funding in support of the Clinical Trial, as set out in Annex 3. All payments shall occur on the conditions as set out in this Annex 3. The Parties agree that no payments are being provided for the purpose of inducing anyone to purchase or prescribe any drugs, devices or products. In addition, Site shall not (i) bill any patient, insurer, or governmental agency for any items, visits, services or expenses provided or paid for by, or on behalf of, Sponsor, or (ii) provide any money or item of value to any government official or representative to improperly influence government actions. In the event that amendments to the Protocol require changes to the Clinical Trial financing arrangements, an amended financial schedule will be agreed upon and signed by the Parties which will replace the existing Annex 3. If the Agreement is terminated for one of the reasons in clauses 12.2, 12.3 or 12.5, except for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)12.2.f, and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, the Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment to the Principal Investigator and/or the Institution up to the date of termination in accordance with Annex 3, and also all expenditure falling due for payment after the date of termination which arises from uncancellable commitments reasonably and necessarily incurred by the Principal Investigator and/or Institution for the performance of the Clinical Trial prior to the date of termination, in accordance with Annex 3. In the case of termination for material breach by the Institution and/or the Principal Investigator under clause 12.2 (f)12.2.f, and subject to an obligation on the Institution and the Principal Investigator to mitigate any loss, Sponsor (through CRO, if applicable) shall pay all fees and expenditures falling due for payment of properly performed services up to the date of the material breach by the Institution and/or the Principal Investigator in accordance with Annex Xxxxx 3. In case of termination for fraud, bribery or corruption, Sponsor will not pay for fees and expenditures directly related to such fraud, bribery or corruption. In the event of early termination, if payment has been made by the Sponsor (through CRO if applicable) to the Institution or the Principal Investigator in advance for work not completed in accordance with Article 13.3, the Institution and/or the Principal Investigator shall issue a credit note and repay the remainder of the monies within 45 days of receipt of written notice from the Sponsor and/or CRO